Floatz logo

48 assets in Myelofibrosis

Therapeutic assets addressing Myelofibrosis, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit
Myelofibrosis
Fred Hutchinson Cancer CenterP2/3B (62)
Cyclophosphamide
Myelofibrosis
City of Hope Medical CenterP3B (62)
Fludarabine
Myelofibrosis
Center for International Blood and Marrow Transplant ResearchP3B (62)
Nivestim
Myelofibrosis
City of Hope Medical CenterP3B (62)
Busulfanum
Myelofibrosis
City of Hope Medical CenterP2B (61)
Cyclosporin A
Myelofibrosis
City of Hope Medical CenterP2B (61)
Melphalan
Myelofibrosis
Center for International Blood and Marrow Transplant ResearchP2B (61)
Luspatercept
Myelofibrosis
CelgeneP3B (60)
Tacrolimus
Myelofibrosis
Stanford UniversityP3B (60)
Ruxolitinib
Myelofibrosis
Center for International Blood and Marrow Transplant ResearchP2B (59)
Sirolimus
Myelofibrosis
Masonic Cancer Center, University of MinnesotaP2B (59)
Hydroxyurea
Myelofibrosis
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.P2B (57)
tq05105 tablets
Myelofibrosis
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.P2B (57)
Cis-Diamminedichloroplatinum Ii
Myelofibrosis
iOncturaP2CCC (55)
Decitabine
Myelofibrosis
Jacqueline Garcia, MDP2CCC (55)
Mesna
Myelofibrosis
Center for International Blood and Marrow Transplant ResearchP2CCC (55)
Fedratinib
Myelofibrosis
University of WashingtonP2CCC (53)
Letermovir
Myelofibrosis
City of Hope Medical CenterP2CCC (52)
Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine
Myelofibrosis
City of Hope Medical CenterP2CCC (52)
Abatacept Recombinant
Myelofibrosis
Center for International Blood and Marrow Transplant ResearchP2CCC (51)
Allopurinol
Myelofibrosis
Masonic Cancer Center, University of MinnesotaP2CCC (51)
Azacitidine
Myelofibrosis
M.D. Anderson Cancer CenterP1/2CCC (51)
Carboplatin
Myelofibrosis
National Cancer Institute (NCI)P2CCC (51)
Nogitecan
Myelofibrosis
National Cancer Institute (NCI)P2CCC (51)
Pacritinib
Myelofibrosis
University of WashingtonP2CCC (51)
Ptcy
Myelofibrosis
Center for International Blood and Marrow Transplant ResearchP2CCC (51)
Veliparib
Myelofibrosis
National Cancer Institute (NCI)P2CCC (51)
Pevonedistat
Myelofibrosis
M.D. Anderson Cancer CenterP1/2CCC (48)
Venetoclax
Myelofibrosis
Jacqueline Garcia, MDP1/2CCC (48)
Itacitinib
Myelofibrosis
City of Hope Medical CenterP2CC (47)
q702
Myelofibrosis
Mayo ClinicP1CC (43)
Anti-Pr1/Hla-A2 Monoclonal Antibody Hu8F4
Myelofibrosis
M.D. Anderson Cancer CenterP1C (39)
ep31670
Myelofibrosis
Epigenetix, Inc.P1C (39)
Glb-001
Myelofibrosis
Hangzhou GluBio Pharmaceutical Co., Ltd.P1C (39)
Ipilimumab
Myelofibrosis
Dana-Farber Cancer InstituteP1C (39)
lp-118
Myelofibrosis
Newave Pharmaceutical IncP1C (39)
Navitoclax
Myelofibrosis
Jacqueline Garcia, MDP1C (39)
Rebecsinib
Myelofibrosis
Aspera Biomedicines, Inc.P1C (39)
Recombinant Human Granulocyte Colony-Stimulating Factor
Myelofibrosis
City of Hope Medical CenterP1C (39)
Roginolisib
Myelofibrosis
iOncturaP1C (39)
Tagraxofusp
Myelofibrosis
Karen Ballen, MDP1C (39)
Tbx-2400
Myelofibrosis
Taiga Biotechnologies, Inc.P1C (39)
Avelumab
Myelofibrosis
iOncturaP1C (38)
Daratumumab
Myelofibrosis
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsEarly P1C (36)
Hyaluronidase Fihj
Myelofibrosis
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsEarly P1C (36)